Secondary analysis of a RCT: Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes.
30 Jun, 2022 | 10:58h | UTCOriginal Study: Empagliflozin in Heart Failure with a Preserved Ejection Fraction – New England Journal of Medicine